|

Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients

RECRUITINGSponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Actively Recruiting
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Started2023-12-31
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07612163

Summary

Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Age over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy

Exclusion Criteria:

Duration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams

Conditions2

Bacterial InfectionsLiver Disease

Interventions1

β-lactams

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.